1
|
Görlitz M, Justen L, Rochette PJ, Buonanno M, Welch D, Kleiman NJ, Eadie E, Kaidzu S, Bradshaw WJ, Javorsky E, Cridland N, Galor A, Guttmann M, Meinke MC, Schleusener J, Jensen P, Söderberg P, Yamano N, Nishigori C, O'Mahoney P, Manstein D, Croft R, Cole C, de Gruijl FR, Forbes PD, Trokel S, Marshall J, Brenner DJ, Sliney D, Esvelt K. Assessing the safety of new germicidal far-UVC technologies. Photochem Photobiol 2024; 100:501-520. [PMID: 37929787 DOI: 10.1111/php.13866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/28/2023] [Accepted: 09/29/2023] [Indexed: 11/07/2023]
Abstract
The COVID-19 pandemic underscored the crucial importance of enhanced indoor air quality control measures to mitigate the spread of respiratory pathogens. Far-UVC is a type of germicidal ultraviolet technology, with wavelengths between 200 and 235 nm, that has emerged as a highly promising approach for indoor air disinfection. Due to its enhanced safety compared to conventional 254 nm upper-room germicidal systems, far-UVC allows for whole-room direct exposure of occupied spaces, potentially offering greater efficacy, since the total room air is constantly treated. While current evidence supports using far-UVC systems within existing guidelines, understanding the upper safety limit is critical to maximizing its effectiveness, particularly for the acute phase of a pandemic or epidemic when greater protection may be needed. This review article summarizes the substantial present knowledge on far-UVC safety regarding skin and eye exposure and highlights research priorities to discern the maximum exposure levels that avoid adverse effects. We advocate for comprehensive safety studies that explore potential mechanisms of harm, generate action spectra for crucial biological effects and conduct high-dose, long-term exposure trials. Such rigorous scientific investigation will be key to determining safe and effective levels for far-UVC deployment in indoor environments, contributing significantly to future pandemic preparedness and response.
Collapse
Affiliation(s)
- Maximilian Görlitz
- Massachusetts Institute of Technology, Media Lab, Cambridge, Massachusetts, USA
- SecureBio, Inc., Cambridge, Massachusetts, USA
| | - Lennart Justen
- Massachusetts Institute of Technology, Media Lab, Cambridge, Massachusetts, USA
- SecureBio, Inc., Cambridge, Massachusetts, USA
| | - Patrick J Rochette
- Centre de recherche du CHU de Québec-Université Laval, Axe Médecine Régénératrice Quebec, Quebec City, Quebec, Canada
| | - Manuela Buonanno
- Center for Radiological Research, Columbia University Medical Center, New York City, New York, USA
| | - David Welch
- Center for Radiological Research, Columbia University Medical Center, New York City, New York, USA
| | - Norman J Kleiman
- Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York City, New York, USA
| | - Ewan Eadie
- Photobiology Unit, Ninewells Hospital, Dundee, UK
| | - Sachiko Kaidzu
- Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan
| | - William J Bradshaw
- Massachusetts Institute of Technology, Media Lab, Cambridge, Massachusetts, USA
- SecureBio, Inc., Cambridge, Massachusetts, USA
| | - Emilia Javorsky
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA
- Future of Life Institute, Cambridge, Massachusetts, USA
| | - Nigel Cridland
- Radiation, Chemicals and Environment Directorate, UK Health Security Agency, Didcot, UK
| | - Anat Galor
- Miami Veterans Affairs Medical Center, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, USA
| | | | - Martina C Meinke
- Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Johannes Schleusener
- Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Paul Jensen
- Final Approach Inc., Port Orange, Florida, USA
| | - Per Söderberg
- Ophthalmology, Department of Surgical Sciences, Uppsala Universitet, Uppsala, Sweden
| | - Nozomi Yamano
- Division of Dermatology, Department of Internal Related, Kobe University, Kobe, Japan
| | - Chikako Nishigori
- Division of Dermatology, Department of Internal Related, Kobe University, Kobe, Japan
- Japanese Red Cross Hyogo Blood Center, Kobe, Japan
| | - Paul O'Mahoney
- Optical Radiation Effects, UK Health Security Agency, Chilton, UK
| | - Dieter Manstein
- Department of Dermatology, Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Rodney Croft
- International Commission on Non-Ionizing Radiation Protection (ICNIRP), Chair, Wollongong, New South Wales, Australia
- University of Wollongong, Wollongong, New South Wales, Australia
| | - Curtis Cole
- Sun & Skin Consulting LLC, New Holland, Pennsylvania, USA
| | - Frank R de Gruijl
- Department of Dermatology, Universiteit Leiden, Leiden, South Holland, The Netherlands
| | | | - Stephen Trokel
- Department of Ophthalmology, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA
| | - John Marshall
- Institute of Ophthalmology, University College London, London, UK
| | - David J Brenner
- Center for Radiological Research, Columbia University Medical Center, New York City, New York, USA
| | - David Sliney
- IES Photobiology Committee, Chair, Fallston, Maryland, USA
- Consulting Medical Physicist, Fallston, Maryland, USA
| | - Kevin Esvelt
- Massachusetts Institute of Technology, Media Lab, Cambridge, Massachusetts, USA
- SecureBio, Inc., Cambridge, Massachusetts, USA
| |
Collapse
|
2
|
Alamil H, Colsoul ML, Heutte N, Van Der Schueren M, Galanti L, Lechevrel M. Exocyclic DNA adducts and oxidative stress parameters: useful tools for biomonitoring exposure to aldehydes in smokers. Biomarkers 2024; 29:154-160. [PMID: 38506499 DOI: 10.1080/1354750x.2024.2333361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Accepted: 03/16/2024] [Indexed: 03/21/2024]
Abstract
CONTEXT Exocyclic DNA adducts have been shown to be potential biomarkers of cancer risk related to oxidative stress and exposure to aldehydes in smokers. In fact, aldehydes potentially arise from tobacco combustion directly and endogenously through lipid peroxidation. OBJECTIVE This study aims to investigate the relationship between a profile of nine aldehydes-induced DNA adducts and antioxidant activities, in order to evaluate new biomarkers of systemic exposure to aldehydes. METHODS Using our previously published UPLC-MS/MS method, adducts levels were quantified in the blood DNA of 34 active smokers. The levels of antioxidant vitamins (A, C and E), coenzyme Q10, β-carotene, superoxide dismutase (SOD) and autoantibodies against oxidized low-density lipoprotein were measured. RESULTS Adducts induced by tobacco smoking-related aldehydes were quantified at levels reflecting an oxidative production from lipid peroxidation. A significant correlation between SOD and crotonaldehyde-induced adducts (p = 0.0251) was also observed. β-Carotene was negatively correlated with the adducts of formaldehyde (p = 0.0351) and acetaldehyde (p = 0.0413). Vitamin C tended to inversely correlate with acetaldehyde-induced adducts (p = 0.0584). CONCLUSION These results are promising, and the study is now being conducted on a larger cohort with the aim of evaluating the impact of smoking cessation programs on the evolution of adducts profile and antioxidants activities.
Collapse
Affiliation(s)
- Héléna Alamil
- Normandie University, UNICAEN, ABTE EA4651, Caen, France
- CCC François Baclesse, UNICANCER, Caen, France
| | | | - Natacha Heutte
- Normandie University, UNIROUEN, CETAPS EA3832, Mont Saint Aignan Cedex, France
| | | | | | - Mathilde Lechevrel
- Normandie University, UNICAEN, ABTE EA4651, Caen, France
- CCC François Baclesse, UNICANCER, Caen, France
| |
Collapse
|
3
|
Ramirez Garcia A, Hurley K, Marastoni G, Diard M, Hofer S, Greppi A, Hardt WD, Lacroix C, Sturla SJ, Schwab C. Pathogenic and Commensal Gut Bacteria Harboring Glycerol/Diol Dehydratase Metabolize Glycerol and Produce DNA-Reactive Acrolein. Chem Res Toxicol 2022; 35:1840-1850. [PMID: 36116084 PMCID: PMC9580524 DOI: 10.1021/acs.chemrestox.2c00137] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Indexed: 12/20/2022]
Abstract
Bacteria harboring glycerol/diol dehydratase (GDH) encoded by the genes pduCDE metabolize glycerol and release acrolein during growth. Acrolein has antimicrobial activity, and exposure of human cells to acrolein gives rise to toxic and mutagenic responses. These biological responses are related to acrolein's high reactivity as a chemical electrophile that can covalently bind to cellular nucleophiles including DNA and proteins. Various food microbes and gut commensals transform glycerol to acrolein, but there is no direct evidence available for bacterial glycerol metabolism giving rise to DNA adducts. Moreover, it is unknown whether pathogens, such as Salmonella Typhymurium, catalyze this transformation. We assessed, therefore, acrolein formation by four GDH-competent strains of S. Typhymurium grown under either aerobic or anaerobic conditions in the presence of 50 mM glycerol. On the basis of analytical derivatization with a heterocyclic amine, all wild-type strains were observed to produce acrolein, but to different extents, and acrolein production was not detected in fermentations of a pduC-deficient mutant strain. Furthermore, we found that, in the presence of calf thymus DNA, acrolein-DNA adducts were formed as a result of bacterial glycerol metabolism by two strains of Limosilactobacillus reuteri, but not a pduCDE mutant strain. The quantification of the resulting adducts with increasing levels of glycerol up to 600 mM led to the production of up to 1.5 mM acrolein and 3600 acrolein-DNA adducts per 108 nucleosides in a model system. These results suggest that GDH-competent food microbes, gut commensals, and pathogens alike have the capacity to produce acrolein from glycerol. Further, the acrolein production can lead to DNA adduct formation, but requires high glycerol concentrations that are not available in the human gut.
Collapse
Affiliation(s)
- Alejandro Ramirez Garcia
- Laboratory
of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
- Laboratory
of Toxicology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Katherine Hurley
- Laboratory
of Toxicology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Giovanni Marastoni
- Laboratory
of Toxicology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Médéric Diard
- Biozentrum, University of Basel, Basel 4056, Switzerland
- Institute
of Microbiology, Department of Biology, ETH Zürich, Zürich 8093, Switzerland
| | - Sophie Hofer
- Laboratory
of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Anna Greppi
- Laboratory
of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Wolf-Dietrich Hardt
- Institute
of Microbiology, Department of Biology, ETH Zürich, Zürich 8093, Switzerland
| | - Christophe Lacroix
- Laboratory
of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Shana J. Sturla
- Laboratory
of Toxicology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
| | - Clarissa Schwab
- Laboratory
of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich 8092, Switzerland
- Department
of Biological and Chemical Engineering, Aarhus University, Aarhus 8000, Denmark
| |
Collapse
|